National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 68021 [2016-23736]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 81, No. 191 / Monday, October 3, 2016 / Notices
required but a specific due date was not
stated.
(2) Any Appendix submitted for Step
1 of the Challenge competition must be
limited to 5 pages or less in length. If
a longer Appendix is submitted, only
the first 5 pages will be considered by
the Technical Evaluation Panel and the
Judging Panel. The September 8, 2016,
announcement incorrectly stated that
there was no page length for the
Appendix material.
(3) Submissions for Step 1 of the
Challenge competition received after the
deadline of January 9, 2017, at 11:59
p.m. ET will be disqualified and not
evaluated by the Technical Evaluation
Panel or Judging Panel.
(4) Solvers may submit corrections or
additional materials in support of their
Step 1 submissions so long as the NIH
receives the materials by the deadline of
January 9, 2017, at 11:59 p.m. ET.
Corrections or additional materials for
Step 1 will not be accepted or evaluated
by the Technical Evaluation Panel or
Judging Panel if they are received after
January 9, 2017 at 11:59 p.m. ET.
(5) The NIH will perform an initial
review of all submissions to ensure they
are complete and within the scope of
the Challenge competition. Submissions
that are incomplete will be
administratively disqualified and will
not be evaluated by the Technical
Evaluation Panel or the Judging Panel.
(6) The NIH and Assistant Secretary
for Preparedness and Response/
Biomedical Advanced Research and
Development Authority may determine
that based on the number of
submissions received for Step 1 that less
competitive submissions will not be
discussed by the Technical Evaluation
Panel during the Panel’s meeting.
(7) The ‘‘Solver’’ needs to address the
NIH Human Subjects Protections and
Inclusion of Women, Children, and
Minorities policies in their submissions
for Step 1 of this competition.
(8) Members of the Technical
Evaluation Panel are not eligible to
participate in or contribute to any
proposal for Step 2 and Step 3 of the
Challenge competition.
(9) Any Solver is eligible for Step 2 of
this Challenge competition. For
example, if a Step 1 ‘‘Solver’’ is not
identified as a semifinalist, he/she may
still submit for Step 2 of this
competition and those who did not
submit a Step 1 proposal may still
submit a proposal for Step 2.
(10) All submissions for Step 1, 2, and
3 must be in English.
For further information about the
Antimicrobial Resistance Diagnostic
Challenge competition, please contact
Robert W. Eisinger, Ph.D., NIH, 301–
VerDate Sep<11>2014
17:56 Sep 30, 2016
Jkt 241001
68021
496–2229 or by email
Robert.eisinger@nih.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 27, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
Substance Abuse and Mental Health
Services Administration
[FR Doc. 2016–23854 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34) and NIAID Investigator
Initiated Program Project Applications (P01).
Date: October 28, 2016.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room # 3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823 Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 27, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23736 Filed 9–30–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
E:\FR\FM\03OCN1.SGM
03OCN1
]]>Agencies
[Federal Register Volume 81, Number 191 (Monday, October 3, 2016)]
[Notices]
[Page 68021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23736]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant
(R34) and NIAID Investigator Initiated Program Project Applications
(P01).
Date: October 28, 2016.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC9823 Bethesda, MD 20892-9823, (240) 669-5068,
zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 27, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-23736 Filed 9-30-16; 8:45 am]
BILLING CODE 4140-01-P
